PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data ...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct ...
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for ...
SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...
PRAGUE & BEIJING--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), ...
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (BHVN) (NYSE: BHVN) and Merus N.V. (MRUS) (Nasdaq:MRUS), today announced a research ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...
For ADC Therapeutics and Aldeyra, ringing in the new year means leaving certain programs behind in 2023. Swiss biotech ADC Therapeutics is discontinuing development of ADCT-901, an antibody drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results